Comparative Pharmacology
Head-to-head clinical analysis: DARIFENACIN versus TOVIAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARIFENACIN versus TOVIAZ.
DARIFENACIN vs TOVIAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing detrusor muscle contractility.
Competitive antagonist of muscarinic acetylcholine receptors (M1-M5), with high selectivity for M3 receptors, reducing detrusor muscle contractions and bladder overactivity.
7.5 mg to 15 mg orally once daily
4 mg orally once daily; may increase to 8 mg once daily based on individual response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 13-19 hours in young adults, increasing to about 17 hours in elderly; supports once-daily dosing.
Clinical Note
moderateDarifenacin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Fluconazole
Terminal elimination half-life of the active metabolite (5-hydroxymethyl tolterodine) is approximately 7-8 hours in extensive CYP2D6 metabolizers and 9-10 hours in poor metabolizers. Clinical context: supports twice-daily dosing for sustained antimuscarinic effect.
Approximately 60% of the dose is excreted renally (as metabolites, primarily 3-hydroxydarifenacin) and 40% fecally; less than 3% excreted unchanged.
Approximately 18% renal excretion of unchanged drug; major elimination via hepatic metabolism (CYP3A4 and CYP2D6) with subsequent biliary/fecal excretion of metabolites. Fecal excretion accounts for ~60% of total elimination, while urinary excretion is <20% as unchanged fesoterodine or active metabolite.
Category C
Category C
Antimuscarinic
Antimuscarinic
"The metabolism of Fluconazole can be decreased when combined with Darifenacin."